RESULTS: VH types included squamous (n¼27), glandular (n¼8), micropapillary (n¼6), sarcomatoid (n¼5), clear cell (n¼4), neuroendocrine (n¼3), nested (n¼1), spindle (n¼1), inverted papilloma (n¼1), and mixed variants (n¼15). VH was more likely to present with extravesical disease (16.9% vs 7.5%, p<0.01), be upstaged at RC (60.6% vs 30.8%, p<0.01), have lymphovascular invasion (LVI) (40.8% vs 28.8%, p<0.01), and lymph node metastasis at RC (28.2% vs 14.4%, p<0.01). The mean days to cystectomy did not differ between PUC and VH (61.1 vs 63.9, p¼0.58). Median follow-up time was 3.5 years. On univariate analysis, for patients with VH, delays greater than 8 weeks were associated with worse OS (HR¼2.20, p¼0.02), while for PUC, only delays greater than 12 weeks reached significance (HR¼1.54, p¼0.04). Multivariable analysis controlling for age, comorbidities, tumor stage, lymph node status, LVI, and surgical margins confirmed worse OS for each month in delay to RC for VH (HR¼1.35, p<0.01). The 5-year overall survival for VH with time to RC of less than 8 weeks was 63% compared to 34% for greater than 8 weeks (p¼0.02).CONCLUSIONS: Variant histology portends a poor prognosis and was more likely to have LVI, be upstaged at RC, and have lymph node metastasis when compared to PUC. Delays in RC greater than 8 weeks for patients with VH were associated with worse overall survival, thus highlighting the need for timely diagnosis and treatment.